Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-l-DOPA11Abbreviations: AAAD, aromatic l-amino acid decarboxylase; BBB, blood-brain barrier; BUI, brain uptake index; carbidopa, l-α-hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid; l-DOPA, l-3,4-dihydroxyphenylalanine; FDA, 6-fluorodopamine; [18F]FDOPA, 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine; 4-[18F]FMT, 4-[18F]fluoro-l-meta-tyrosine; 6-[18F]FMT, 6-[18F]fluoro-l-meta-tyrosine; MeAIB, α-(methylamino)isobutyric acid; MPTP, 1-me

Yee, Randa E.; Cheng, De; Huang, Sung‐Cheng; Namavari, Mohammad; Satyamurthy, Nagichettiar; Barrio, Jorge R.

doi:10.1016/s0006-2952(01)00787-0

Cited by 30 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the ventral-medial DRN sub-region projects densely to the basal ganglia structures and motor cortices [ 37 ], while the dorsal-medial DRN sends axons to limbic areas such as the amygdala, nucleus accumbens, and medial-prefrontal cortex [ 38 ]. However, as previously mentioned, all 5-HT neurons are similar in that they possess the ability to uptake l -dopa [ 39 ], decarboxylate it to dopamine [ 40 ], and package the dopamine into vesicles for exocytotic release [ 41 ].…”

Section: L -Dopa Treatment In Pdmentioning

confidence: 99%

L-Dopa and Brain Serotonin System Dysfunction

Stansley

Yamamoto

2015

Toxics

View full text Add to dashboard Cite

l-dopa is used to treat the motor symptoms associated with Parkinson’s disease, a neurodegenerative movement disorder characterized by a loss of dopamine neurons. l-dopa is the precursor to dopamine and crosses the blood-brain barrier to increase dopamine neurotransmission. This review will focus on the findings that dopamine produced from l-dopa is mediated in part by serotonin neurons. Direct evidence will be provided that increases in dopamine cause oxidative stress and damage serotonin neurons. Similarly, chronic l-dopa produces deficits in serotonin neurotransmission, including decreases in both serotonin cell bodies within the dorsal raphe and serotonin neurotransmitter concentrations in several forebrain regions. Since serotonin is involved in many important physiological processes including mood and cognition, l-dopa induced serotonin deficits may play a role in the side-effect symptoms observed in Parkinson’s disease patients treated with l-dopa.

show abstract

Section: L -Dopa Treatment In Pdmentioning

confidence: 99%

L-Dopa and Brain Serotonin System Dysfunction

Stansley

Yamamoto

2015

Toxics

View full text Add to dashboard Cite

show abstract

“…Furthermore, the disruption of the blood-brain barrier is the mechanism suggested for the higher FET washout in HGG compared to LGG (31). However, the tumor accumulation of FDOPA in gliomas is also mediated through the specific LAT transport system, a tight bidirectional coupling of influx and efflux with obligatory exchange (32,33). The estimates for the contribution of blood-brain barrier disruption and the specific LAT transport system contribution to the FDOPA uptake and washout in gliomas are not fully understood (34).…”

Section: Discussionmentioning

confidence: 99%

Additive Value of Dynamic FDOPA PET/CT for Glioma Grading

et al. 2021

View full text Add to dashboard Cite

Purpose: The aim of this study was to assess the value of the FDOPA PET kinetic parameters extracted using full kinetic analysis for tumor grading with neuronavigation-guided biopsies as reference in patients with newly-diagnosed gliomas.Methods: Fourteen patients with untreated gliomas were investigated. Twenty minutes of dynamic positron-emission tomography (PET) imaging and a 20-min static image 10 min after injection were reconstructed from a 40-min list-mode acquisition immediately after FDOPA injection. Tumors volume-of-interest (VOI) were generated based on the MRI-guided brain biopsies. Static parameters (TBRmax and TBRmean) and kinetic parameters [K1 and k2 using full kinetic analysis with the reversible single-tissue compartment model with blood volume parameter and the time-to-peak (TTP)] were extracted. Performances of each parameter for differentiating low-grade gliomas (LGG) from high-grade gliomas (HGG) were evaluated by receiver-operating characteristic analyses (area under the curve; AUC).Results: Thirty-two tumoral VOI were analyzed. K1, k2, and TTP were significantly higher for HGG than for LGG (median K1-value = 0.124 vs. 0.074 ml/ccm/min, p = 0.025, median k2-value = 0.093 vs. 0.063 min−1, p = 0.025, and median TTP-value = 10.0 vs. 15.0 min, p = 0.025). No significant difference was observed for the static parameters. The AUC for the kinetic parameters was higher than the AUC for the static parameters (respectively, AUCK1 = 0.787, AUCk2 = 0.785, AUCTTP = 0.775, AUCTBRmax = 0.551, AUCTBRmean = 0.575), significantly compared to TBRmax (respectively, p = 0.001 for K1, p = 0.031 for k2, and p = 0.029 for TTP).Conclusion: The present study suggests an additive value of FDOPA PET/CT kinetic parameters for newly-diagnosed gliomas grading.

show abstract

“…One important advantage however is that tracer uptake is independent of blood–brain barrier breakdown, thus facilitating radiotracer uptake independent of tumor enhancement on contrast MRI studies. [11]…”

Section: Discussionmentioning

confidence: 99%

Novel positron emission tomography radiotracers in brain tumor imaging

D’Souza

Sharma

Tripathi

et al. 2011

Indian Journal of Radiology and Imaging

View full text Add to dashboard Cite

Although [18F] 2-fluoro-2-deoxy-D-glucose (FDG) is the most widely used radiopharmaceutical the world over, it is not the ideal tracer for brain imaging, owing to its high physiological cortical uptake and lack of specificity. This has paved the way for the introduction of several novel radiotracers, each with their own inherent strengths and limitations. We present the insights gained from the use of these radiotracers at our institution.

show abstract

Cited by 30 publications

References 38 publications

L-Dopa and Brain Serotonin System Dysfunction

L-Dopa and Brain Serotonin System Dysfunction

Additive Value of Dynamic FDOPA PET/CT for Glioma Grading

Novel positron emission tomography radiotracers in brain tumor imaging

Contact Info

Product

Resources

About